The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome

Inclusion Criteria

• •1. Female, aged 18 to 75
• •2. Her-2 negative patients with non metastatic breast cancer.
• •3. patients with early breast cancer who did not receive PCR after neoadjuvant chemotherapy or patients with lymph node metastasis after breast cancer surgery.
• •4. Prepare to receive postoperative adjuvant single drug capecitabine or capecitabine combined with endocrine therapy and / or radiotherapy
• •The Binbin dose is 1000mg / ㎡, bid (continuous oral administration for 14 days, stopping for 7 days, repeated every 21 days)
• •5. Eastern cancer cooperation group (ECoG) physical strength score 0-1;
• •6. During randomization, the toxicity related to previous treatment must be alleviated to NCI CTCAE (version 4.03) ≤ 1 degree (except hair loss or according to the research)
• •Other toxicity judged by the investigator that there is no risk to the safety of the patient);
• •7. Blood routine examination was basically normal within 4 weeks before enrollment: A. white blood cell count (WBC) ≥ 3.0 × 10 \^ 9 / L, B. medium
• •Sex granulocyte count (ANC) ≥ 1.5 × 10 \^ 9 / L, C. platelet count (PLT) ≥ 100 × 10\^9／L;
• •8. The liver and kidney function tests were basically normal within 4 weeks before enrollment (based on the normal values in the laboratories of each research center): a
• •Total bilirubin (TBIL) ≤ 1.5 × Upper limit of normal value (ULN), B. alanine aminotransferase and aspartate aminotransferase (ALT / AST)
• •≤2.5 × ULN (patients with liver metastasis) ≤ 5 × ULN), C. serum creatinine ≤ 1.5 × ULN or creatinine clearance (CCR)
• •≥60 ml/min；
• •9. Women of childbearing age must have a serum / urine pregnancy test 4 weeks before enrollment, and the result is negative, and are willing to participate in the study
• •Use a medically recognized high-efficiency contraceptive during and within 6 months after the last administration of the drug;
• •10. Informed consent has been signed before joining the group;
• •11. There was no active infectious disease within 12 weeks of screening period